AI Analysis | Feedback

Here are 1-2 brief analogies for Cocrystal Pharma (COCP):

• Gilead Sciences for novel small molecule antivirals.
• Moderna or BioNTech for small molecule antiviral drugs.

AI Analysis | Feedback

• COVID-19 Antivirals: Developing oral, small molecule direct-acting antivirals, such as CC-42344, for the treatment of COVID-19.
• Influenza Antivirals: Developing novel, oral, broad-spectrum antivirals, such as CC-24754, for the treatment of influenza A and B.
• Norovirus Antivirals: Developing oral, direct-acting antiviral candidates for the treatment of norovirus infections.

AI Analysis | Feedback

Cocrystal Pharma (COCP) is a clinical-stage biotechnology company focused on discovering and developing novel antiviral therapeutics. As such, it does not currently sell commercialized products directly to individuals or to traditional healthcare providers like pharmacies or hospitals.

Instead, Cocrystal Pharma primarily generates revenue through collaborations, licensing agreements with larger pharmaceutical companies, and government grants for research and development. Therefore, the company sells primarily to other companies and institutions.

Based on their latest public filings (e.g., 2023 10-K), a major customer and partner is:

• Merck & Co., Inc. (Symbol: MRK) - Cocrystal Pharma entered into an exclusive worldwide license agreement with Merck for certain proprietary influenza antiviral agents. Under this agreement, Cocrystal Pharma received an upfront payment and is eligible to receive significant development and sales milestones, plus royalties on net sales.

Additionally, Cocrystal Pharma has received significant funding in the form of grants from organizations such as the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of antiviral compounds.

AI Analysis | Feedback

null

AI Analysis | Feedback

Sam Lee, Ph.D. Co-Chief Executive Officer and President

Dr. Sam Lee has over 25 years of anti-infective drug discovery research experience. Prior to Cocrystal Pharma, he managed anti-infective drug discovery projects for eight years at Icos Corporation (Nasdaq: ICOS), which was later acquired by Eli Lilly in 2007. At Icos, Dr. Lee played a key role in developing phosphoinositide 3-kinase (PI3K) delta inhibitors, which yielded an FDA-approved product. While completing postdoctoral training in viral biochemistry at Stanford University, Dr. Lee founded and served as CEO of Viral Assays in Cupertino, CA.

James J. Martin Co-Chief Executive Officer and Chief Financial Officer

Mr. James Martin has over 25 years of finance and management experience, including providing financial leadership to commercial-stage, publicly traded health science companies. Prior to joining Cocrystal Pharma, Mr. Martin served as the Chief Financial Officer of Motus GI (Nasdaq: MOTS), a medical device company. From September 2014 to November 2016, he was the Chief Financial Officer of VBI Vaccines, Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq: VBIV), a pharmaceutical development and manufacturing company. Mr. Martin also served as Chief Financial Officer of Vapor Corp, Inc. (Nasdaq: VPCO) from April 2014 to September 2015, and as Chief Financial Officer of SafeStitch from January 2011 to October 2013, prior to its merger with TransEnterix, Inc. (NYSE: TRXC). He also serves as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. (OTC Pink: NIMU), a company marketing non-invasive medical devices.

AI Analysis | Feedback

Key Business Risks for Cocrystal Pharma (COCP)

Cocrystal Pharma (COCP) faces several significant business risks, primarily stemming from its financial condition, the inherent uncertainties of drug development, and competitive pressures within the biopharmaceutical industry. The most critical risks include the company's need for continuous fundraising, the challenges associated with successful clinical trials and regulatory approvals, and the potential for competitive therapies or viral resistance.

1. Financial Sustainability and Need for Additional Capital: Cocrystal Pharma has a history of operating losses and has not yet generated revenue from product sales, financing its operations primarily through equity sales and collaborations. The company's recent financial statements show continuing net losses, with its cash position potentially insufficient to fund operations beyond the next 12 months without securing additional capital. This ongoing need for fundraising raises substantial doubts about the company's ability to sustain operations in the long term.
2. Clinical Trial Success and Regulatory Approval: As a clinical-stage biotechnology company, Cocrystal Pharma's future revenue generation is critically dependent on the successful completion of clinical trials and subsequent regulatory approvals for its product candidates. All of its drug candidates are in preclinical or early clinical stages. Risks include adverse findings or delays in studies, difficulties in recruiting volunteers for trials, challenges in manufacturing necessary products, and the general uncertainties inherent in the complex and lengthy drug development and approval process. An example of these challenges includes the extension of a Phase 2a human challenge study for one of its influenza drug candidates due to lower-than-expected infection rates among participants, rendering initial results uninterpretable.
3. Competition and Viral Resistance: The biopharmaceutical industry is highly competitive. Cocrystal Pharma faces risks from the development of effective treatments and/or vaccines by competitors. Additionally, there is an ongoing risk that the viruses targeted by the company's drug candidates could mutate, leading to the emergence of variants resistant to the developed product candidates, thereby diminishing their effectiveness.

AI Analysis | Feedback

• Accelerated development and adoption of novel therapeutic modalities (e.g., mRNA-based antivirals, gene editing technologies): While Cocrystal Pharma focuses on small molecule direct-acting antivirals, significant advancements are occurring in alternative therapeutic platforms. mRNA technology, proven effective in vaccines, is being explored for direct antiviral therapies or for delivering prophylactic antibodies. Gene editing technologies (like CRISPR) are also under investigation for their potential to target and eliminate viral genetic material within host cells. If these fundamentally different approaches mature and demonstrate superior efficacy, broader spectrum activity, or more convenient administration compared to small molecules, they could represent a significant disruptive threat to the market for Cocrystal's pipeline candidates. The ongoing, substantial investment and research in these areas by numerous biotech and pharma companies provide clear evidence of this emerging threat.

• Intensifying competition from large pharmaceutical companies with significantly greater resources and advanced, diverse pipelines: Large pharmaceutical companies (e.g., Pfizer, Merck, Gilead, Roche) continuously invest vast sums in infectious disease research and development. They often have multiple candidates targeting the same viral indications as Cocrystal (e.g., influenza, COVID-19, norovirus) and can accelerate their programs due to their extensive financial, scientific, and regulatory expertise. This allows them to bring next-generation antivirals to market more quickly, often with improved profiles (e.g., better tolerability, broader spectrum, convenient dosing). The sheer scale and speed of their R&D and commercialization efforts, coupled with their established market presence and distribution networks, pose an ongoing and escalating challenge for a smaller company like Cocrystal Pharma to differentiate its products, secure market share, and compete effectively. This isn't just static competition but an emerging intensification of the competitive landscape driven by their large-scale R&D efforts.

AI Analysis | Feedback

Cocrystal Pharma (COCP) is a clinical-stage biotechnology company developing novel antiviral therapeutics. Their main product candidates target norovirus, coronavirus, and influenza.

• Norovirus (CDI-988)
  • The global market for norovirus represents a significant opportunity with a worldwide economic impact estimated at $60 billion annually, linked to 685 million global cases each year.
  • In the U.S. alone, noroviruses are responsible for an estimated 21 million cases annually, with an annual burden of $10.6 billion.
• Coronaviruses, including COVID-19 (CDI-988)
  • The global COVID-19 therapeutics market is estimated to exceed $16 billion annually by the end of 2031.
• Influenza (CC-42344 and other programs)
  • Globally, there are approximately 1 billion cases of seasonal influenza each year.
  • In the U.S., influenza is responsible for an estimated $11.2 billion in direct and indirect costs annually.
  • The seasonal influenza market size across the 7MM (United States, EU-5, and Japan) was approximately USD 6,646 million in 2021.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Cocrystal Pharma (COCP)

1. Advancement of CDI-988 for Norovirus: Cocrystal Pharma is developing CDI-988 as a potential first-in-class treatment and prophylaxis for norovirus infections. The company plans to initiate a human challenge Phase 1b study in the U.S. in 2025 to evaluate CDI-988. This compound has demonstrated superior broad-spectrum antiviral activity against major norovirus variants, including recently re-emerging GII.17 strains prevalent in 2024-2025 outbreaks. The absence of any approved norovirus treatments or vaccines presents a substantial market opportunity, with an estimated 685 million global cases annually and a $60 billion worldwide economic impact. Successful progression through clinical trials and eventual regulatory approval would be a significant revenue driver.
2. Development of CDI-988 for Coronavirus: Leveraging its proprietary structure-based drug discovery platform, Cocrystal Pharma is also developing CDI-988 for coronavirus infections, including SARS-CoV-2. The Phase 1 study for CDI-988 is expected to serve as a study for both norovirus and coronavirus indications, having shown superior in vitro potency against SARS-CoV-2 and a favorable safety profile. The global COVID-19 therapeutics market is estimated to exceed $16 billion annually by the end of 2031, representing a substantial potential market if CDI-988 proves effective and gains approval.
3. Advancement of Broad-Spectrum Influenza Treatments: Cocrystal Pharma continues to advance its antiviral drug-development programs for influenza. The company's pipeline includes broad-spectrum influenza treatments designed to disrupt viral replication mechanisms. While one candidate (CC-42344) encountered setbacks in a Phase 2a study, ongoing efforts in this area, utilizing their structure-based drug discovery platform, could yield future revenue if successful candidates emerge and progress through clinical development.
4. Strategic Partnerships and Non-Dilutive Funding: The company's strategy includes securing non-dilutive capital and engaging in collaborations. Recent awards, such as a non-dilutive award intended to assess scientific, technical, and commercial potential, validate its drug discovery platform. Future partnerships with larger pharmaceutical companies could provide significant funding, milestone payments, and royalties upon successful development and commercialization of their antiviral candidates, thereby contributing to future revenue.

AI Analysis | Feedback

Share Issuance

• On October 30, 2025, Cocrystal Pharma completed a private placement, raising $1.03 million by selling 743,024 common shares at $1.39 per unit. Concurrently, the company issued unregistered warrants to purchase up to 1,486,048 shares at an exercise price of $1.24 per share, which could bring in approximately $1.83 million more if fully exercised.
• The company closed a registered direct offering on September 15, 2025, selling 2,764,710 shares of common stock at $1.70 per share, resulting in approximately $4.7 million in gross proceeds.
• In a concurrent private placement related to the September 2025 offering, Cocrystal Pharma issued unregistered warrants to purchase up to 5,529,420 shares of common stock at an exercise price of $1.50 per share, with the potential to generate an additional $8.3 million if fully exercised.

Inbound Investments

• On October 27, 2025, Cocrystal Pharma received a non-dilutive NIH/NIAID SBIR Phase I award of approximately $500,000. These funds are allocated to support the development of a novel, oral, broad-spectrum antiviral candidate for influenza A and B.